Helixmith Is A Gene Therapy Company Headquartered In Seoulkoreadeveloping New And Innovative Biopharmaceuticals For Previously Untreated Diseasesand Is Listed On Kosdaqthe Company Has An Extensive Gene Therapy Pipelineincluding A Car T Program Targeting Several Different Types Of Solid Tumors And An Aav Vector Program Targeting Neuromuscular Diseasesengensisvm202 A More Advanced Pipeline Candidateis A Plasmid Dna Therapy Being Studied For Dpndiabetic Foot Ulcersclaudicationamyotrophic Lateral Sclerosisphase 2 Beginning In Late 2020 Coronary Artery Disease And Charcot Marie Tooth Diseasehelixmith Clinical Development Activities Are Based In San Diegocalifornia
